[Date Prev][Date Next][Thread Prev][Thread Next][Date Index][Thread Index]
A5 with high-LET radiation
- To: "'Andy Loebl'" <loeblas@ornl.gov>, Aaron Bertrand Brill <aaron.brill@vanderbilt.edu>, kirkbl@ornl.gov, "Rivard, Mark PhD" <MRivard@Lifespan.org>, "'M. Stabin'" <michael.g.stabin@vanderbilt.edu>, "'Trent Nichols'" <tlnichol@utkux.utcc.utk.edu>, "'Doug Henderson'" <henderson@engr.wisc.edu>, ingersolldt@ornl.gov, trmackie@facstaff.wisc.edu, peplowde@ornl.gov, coderre@MIT.EDU, charles.coffey@mcmail.vanderbilt.edu
- Subject: A5 with high-LET radiation
- From: "Rivard, Mark PhD" <MRivard@Lifespan.org>
- Date: Fri, 13 Jul 2001 11:14:27 -0400
I propose to place this paragraph into A5 following Rock's paragraph
describing a virtual clinical trial.
Please let me know if this should be expanded, changed, or supported with
references.
Efforts are made to explore novel means of calculating, administering, and
analyzing effects of conventional, low-linear energy transfer (LET)
radiation. While the investigators encompass diverse backgrounds, many have
experience with high-LET radiation. One likely result of subsequent
projects for this program is to take advantage of this opportunity. 252Cf
is a radionuclide which emits both low- and high-LET radiation. Though its
use up until now has been greatly limited due to concerns for personnel
exposure, ORNL has developed techniques to overcome this obstacle and permit
treatments with high-LET radiation which may be safe, cost-effective, and be
therapeutically advantageous. Our collaboration and use of CoNCeRT may
provide the chance to assess this novel therapeutic modality.